Brief: Oncolytics Biotech reports updated data from Phase 2 study of REOLYSIN
April 14 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Analysis showed a statistically significantly higher
percentage of patients surviving two years in test arm versus
control arm
* Says at time of data cut off, there were five survivors on
study in test arm, and one survivor on study in crossover arm
* Two- and three-year survival for arms may continue to
evolve
Source text for Eikon: ID:nCNWKdQkja
Further company coverage: ONC.TO
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer